Since it became clear that the business plan changed from marketing ph20/insulin and partner peg after phase II to partner ph20/insulin and bring peg to market.
How does little Halo run multiple worldwide clinical/registration trials and commercialize peg? imo, they don't. Keep the US market, I think they have a base in place for that. Partner for the EU/ROW with high upfront, milestone and royalty payments.
The EU orphan designation is the start of that process imo. We now have working relationships with several partners big enough to quickly move peg programs through the EU/ROW while Halo develops the US market.
Halo is doing pre-clinical with Herceptin. The PD-L1 drug combo for 2015 trial start may give a clue to who is most interested.
Of course efficacy must be proven in the PAG trial before any of this is possible.
News 
Market Data 
Discover 
